Scinai Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Scinai Immunotherapeutics
SCNI Stock  USD 0.76  0.04  5.00%   
Scinai Immunotherapeuti's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Scinai Immunotherapeuti's valuation are provided below:
Gross Profit
-1.7 M
Profit Margin
4.4839
Market Capitalization
2.5 M
Enterprise Value Revenue
8.503
Revenue
1.1 M
We have found one hundred twenty available fundamental trend indicators for Scinai Immunotherapeutics, which can be analyzed and compared to other ratios and to its competition. Traders should compare all of Scinai Immunotherapeutics current fundamentals against the fundamentals between 2010 and 2025 to make sure the company is sustainable this year. The current Market Cap is estimated to decrease to about 2.6 M. Enterprise Value is estimated to decrease to about 2.7 M

Scinai Immunotherapeuti Total Revenue

1.07 Million

Check Scinai Immunotherapeuti financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Scinai Immunotherapeuti's main balance sheet or income statement drivers, such as Interest Expense of 1 M, Selling General Administrative of 4.2 M or Total Revenue of 1.1 M, as well as many indicators such as Price To Sales Ratio of 3.29, Dividend Yield of 0.0 or PTB Ratio of 0.26. Scinai financial statements analysis is a perfect complement when working with Scinai Immunotherapeuti Valuation or Volatility modules.
  
Build AI portfolio with Scinai Stock
Check out the analysis of Scinai Immunotherapeuti Correlation against competitors.

Scinai Immunotherapeuti Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets12 M13.4 M15.6 M
Slightly volatile
Total Current Liabilities2.4 M1.8 M2.9 M
Slightly volatile
Accounts Payable357.2 K376 K1.1 M
Pretty Stable
Cash1.9 M2 M8 M
Pretty Stable
Long Term Debt247 K260 K80 M
Slightly volatile
Total Liabilities3.3 M3.5 M13.3 M
Slightly volatile
Common Stock5.3 M9.6 M7.8 M
Pretty Stable
Other Current Liabilities478.5 K781 K399.3 K
Slightly volatile
Other Assets571.1 K544 K220.9 K
Slightly volatile
Other Current Assets251.5 K210 K300.6 K
Very volatile
Intangible Assets3.2 K3.4 K25.3 K
Slightly volatile
Property Plant Equipment12.7 M14.6 M30.7 M
Slightly volatile
Property Plant And Equipment Net5.9 M11.1 M6 M
Slightly volatile
Non Current Assets Total6.3 M11.1 M6.3 M
Slightly volatile
Cash And Short Term Investments1.9 M2 M8.8 M
Pretty Stable
Net Receivables206.2 K217 K587 K
Pretty Stable
Common Stock Shares Outstanding846.7 K806.4 K174.6 K
Slightly volatile
Short Term Investments2.4 M2.2 M2.2 M
Pretty Stable
Liabilities And Stockholders Equity16.7 M13.4 M16.1 M
Slightly volatile
Non Current Liabilities Total1.6 M1.7 M10.4 M
Slightly volatile
Other Stockholder Equity129.8 M123.6 M63.5 M
Slightly volatile
Total Current Assets2.3 M2.4 M9.2 M
Pretty Stable
Short and Long Term Debt Total2 M2.1 M22.6 M
Slightly volatile
Other Liabilities4.6 M4.8 M21.2 M
Slightly volatile
Capital Lease Obligations2.7 M1.8 M5.7 M
Slightly volatile
Net Invested Capital4.4 M4.6 M45.6 M
Slightly volatile
Property Plant And Equipment Gross21.4 M15.5 M38 M
Slightly volatile
Non Current Liabilities Other11.8 M13.3 M14.5 M
Slightly volatile
Short Term Debt402.8 K424 K1.5 M
Pretty Stable
Short and Long Term Debt15 M16.9 M18.4 M
Slightly volatile
Current Deferred Revenue180 K202.5 K220.8 K
Slightly volatile

Scinai Immunotherapeuti Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative4.2 M2.5 M4.3 M
Slightly volatile
Research Development4.6 M5.5 M6.1 M
Slightly volatile
Cost Of Revenue1.3 M1.2 M426.2 K
Slightly volatile
Depreciation And Amortization1.7 M1.6 M449.2 K
Slightly volatile
Other Operating Expenses7.3 M9.3 M7.3 M
Slightly volatile
Selling And Marketing Expenses78.6 K82.8 K6.5 M
Very volatile
Interest Income95 K100 K426.3 K
Slightly volatile
Reconciled Depreciation1.2 M1.6 M1.6 M
Pretty Stable

Scinai Immunotherapeuti Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Change To Inventory598.8 K664.7 K563 K
Slightly volatile
End Period Cash Flow2 M2.1 M9.4 M
Very volatile
Begin Period Cash Flow9.2 M5 M8.9 M
Slightly volatile
Depreciation1.7 M1.6 M467.8 K
Slightly volatile
Stock Based Compensation963.5 K682 K861.6 K
Slightly volatile
Change To Operating Activities619.6 K351.9 K292.1 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio3.293.694.0284
Slightly volatile
Days Sales Outstanding96.3108118
Slightly volatile
Invested Capital6.2 M6.1 M5.5 M
Very volatile
Average Payables532.3 K711.1 K818.1 K
Pretty Stable
Stock Based Compensation To Revenue0.830.931.0169
Slightly volatile
Capex To Depreciation0.00690.00737.3388
Very volatile
EV To Sales3.433.864.2101
Slightly volatile
Inventory Turnover62.3 K91.5 K95.6 K
Very volatile
Days Of Inventory On Hand0.00780.00410.0041
Pretty Stable
Payables Turnover3.463.29260.7676
Slightly volatile
Average Inventory0.410.430.462
Slightly volatile
Research And Ddevelopement To Revenue6.737.578.2501
Slightly volatile
Capex To Revenue0.01460.01640.0179
Slightly volatile
Cash Per Share2.312.4356238
Slightly volatile
Days Payables Outstanding1051114.2 K
Pretty Stable
Tangible Asset Value7 M6.8 M6.2 M
Very volatile
Intangibles To Total Assets7.0E-47.0E-40.001
Slightly volatile
Current Ratio1.261.32398.8723
Slightly volatile
Receivables Turnover2.422.732.9751
Slightly volatile
Graham Number0.00820.00920.01
Slightly volatile
Capex Per Share0.01410.014916.9436
Pretty Stable
Average Receivables153.6 K146.3 K196 K
Slightly volatile
Revenue Per Share0.660.730.8009
Slightly volatile
Interest Debt Per Share4.154.3712105
Slightly volatile
Debt To Assets0.150.15510.8455
Slightly volatile
Operating Cycle114108112
Slightly volatile
Days Of Payables Outstanding1051114.2 K
Pretty Stable
Pretax Profit Margin5.836.567.152
Slightly volatile
Long Term Debt To Capitalization0.02410.02541.2464
Slightly volatile
Total Debt To Capitalization0.160.17291.274
Slightly volatile
Quick Ratio1.261.32398.8723
Slightly volatile
Cash Ratio1.031.08755.8252
Slightly volatile
Days Of Inventory Outstanding0.00780.00410.0041
Pretty Stable
Days Of Sales Outstanding96.3108118
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.221.00191.1179
Very volatile
Fixed Asset Turnover0.04760.05360.0584
Slightly volatile
Debt Ratio0.150.15510.8455
Slightly volatile
Price Sales Ratio3.293.694.0284
Slightly volatile
Asset Turnover0.03910.0440.048
Slightly volatile
Net Profit Margin5.836.567.152
Slightly volatile

Scinai Immunotherapeuti Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap2.6 M2.7 M6.8 M
Slightly volatile
Enterprise Value2.7 M2.8 M7.9 M
Slightly volatile

Scinai Fundamental Market Drivers

Scinai Upcoming Events

15th of April 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About Scinai Immunotherapeuti Financial Statements

Investors use fundamental indicators, such as Scinai Immunotherapeuti's revenue or net income, to determine how well the company is positioned to perform in the future. Although Scinai Immunotherapeuti's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Current Deferred Revenue202.5 K180 K
Total Revenue658 K1.1 M
Cost Of Revenue1.2 M1.3 M
Stock Based Compensation To Revenue 0.93  0.83 
Research And Ddevelopement To Revenue 7.57  6.73 
Capex To Revenue 0.02  0.01 
Revenue Per Share 0.73  0.66 
Ebit Per Revenue(11.81)(12.41)

Currently Active Assets on Macroaxis

DDDupont De Nemours
CRDOCredo Technology Group
GOOGAlphabet Inc Class C
BACBank of America
CRMSalesforce
When determining whether Scinai Immunotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Scinai Immunotherapeuti's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Scinai Immunotherapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Scinai Immunotherapeutics Stock:
How To Invest In Scinai
Details
Is Scinai Stock a good investment?
Details
What is Scinai Immunotherapeuti's Net Worth?
Details
Largest Semiconductors & Semiconductor Equipment Companies
View
Largest Information Technology Companies
View
Check out the analysis of Scinai Immunotherapeuti Correlation against competitors.
You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Semiconductors & Semiconductor Equipment space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Scinai Immunotherapeuti. If investors know Scinai will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Scinai Immunotherapeuti listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.872
Earnings Share
4
Quarterly Revenue Growth
0.361
Return On Assets
(0.40)
Return On Equity
0.1792
The market value of Scinai Immunotherapeutics is measured differently than its book value, which is the value of Scinai that is recorded on the company's balance sheet. Investors also form their own opinion of Scinai Immunotherapeuti's value that differs from its market value or its book value, called intrinsic value, which is Scinai Immunotherapeuti's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Scinai Immunotherapeuti's market value can be influenced by many factors that don't directly affect Scinai Immunotherapeuti's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Please note, there is a significant difference between Scinai Immunotherapeuti's value and its price as these two are different measures arrived at by different means. Investors typically determine if Scinai Immunotherapeuti is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Scinai Immunotherapeuti's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY